- Home
- PINE vs IMMP Comparison
PINE vs IMMP Comparison
Compare PINE & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- IMMP
- Stock Information
- Founded
- PINE 2019
- IMMP 1987
- Country
- PINE United States
- IMMP Australia
- Employees
- PINE N/A
- IMMP N/A
- Industry
- PINE Real Estate Investment Trusts
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- IMMP Health Care
- Exchange
- PINE Nasdaq
- IMMP Nasdaq
- Market Cap
- PINE 232.7M
- IMMP 256.1M
- IPO Year
- PINE 2019
- IMMP N/A
- Fundamental
- Price
- PINE $16.59
- IMMP $1.77
- Analyst Decision
- PINE Strong Buy
- IMMP Buy
- Analyst Count
- PINE 3
- IMMP 1
- Target Price
- PINE $17.17
- IMMP $7.00
- AVG Volume (30 Days)
- PINE 116.3K
- IMMP 138.2K
- Earning Date
- PINE 10-23-2025
- IMMP 02-22-2026
- Dividend Yield
- PINE 6.88%
- IMMP N/A
- EPS Growth
- PINE N/A
- IMMP N/A
- EPS
- PINE N/A
- IMMP N/A
- Revenue
- PINE $57,423,000.00
- IMMP $3,306,742.00
- Revenue This Year
- PINE $14.05
- IMMP N/A
- Revenue Next Year
- PINE $1.11
- IMMP N/A
- P/E Ratio
- PINE N/A
- IMMP N/A
- Revenue Growth
- PINE 14.81
- IMMP 31.28
- 52 Week Low
- PINE $13.10
- IMMP $1.32
- 52 Week High
- PINE $18.24
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- PINE 83.28
- IMMP 42.34
- Support Level
- PINE $16.07
- IMMP $1.78
- Resistance Level
- PINE $16.59
- IMMP $1.95
- Average True Range (ATR)
- PINE 0.41
- IMMP 0.09
- MACD
- PINE 0.17
- IMMP -0.00
- Stochastic Oscillator
- PINE 96.70
- IMMP 36.36
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.